National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 1982 [2021-00222]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
1982
Federal Register / Vol. 86, No. 6 / Monday, January 11, 2021 / Notices
exposed to chemicals as mixtures.
Assessing the safety of a mixture is a
complex process that requires
consideration of both the toxicity of
each chemical component of the
mixture and the potential for interaction
among the components to affect toxicity
of the overall mixture. Additionally,
most alternative methods and
approaches used for assessing chemical
safety are developed and evaluated
using single chemicals. This can result
in lack of clarity about whether a
method is appropriate to use for
assessing toxicity of a particular
mixture.
This webinar will discuss new
approach methodologies for assessing
exposure to, and potential hazards
associated with, chemical mixtures. Key
insights and ongoing activities will be
described in three presentations
featuring speakers from U.S. federal
research and regulatory agencies. The
preliminary agenda and additional
information about presentations will be
posted at https://ntp.niehs.nih.gov/go/
commprac-2021 as available.
Webinar and Registration: This
webinar is open to the public with time
scheduled for questions by participants
following each presentation.
Registration for the webinar is required
and will be open from January 4, 2021,
through 11:00 a.m. EST on January 26,
2021. Registration is available at https://
ntp.niehs.nih.gov/go/commprac-2021.
Interested individuals are encouraged to
visit this web page to stay abreast of the
most current webinar information.
Registrants will receive instructions on
how to access and participate in the
webinar in the email confirming their
registration.
Background Information on ICCVAM
and NICEATM: ICCVAM is an
interagency committee composed of
representatives from 17 federal
regulatory and research agencies that
require, use, generate, or disseminate
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability. ICCVAM also
promotes the scientific validation and
regulatory acceptance of testing
methods that more accurately assess the
safety and hazards of chemicals and
products and replace, reduce, or refine
(enhance animal well-being and lessen
or avoid pain and distress) animal use.
The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) establishes
ICCVAM as a permanent interagency
committee of NIEHS and provides the
authority for ICCVAM involvement in
activities relevant to the development of
VerDate Sep<11>2014
22:36 Jan 08, 2021
Jkt 253001
alternative test methods. Additional
information about ICCVAM can be
found at https://ntp.niehs.nih.gov/go/
iccvam.
NICEATM administers ICCVAM,
provides scientific and operational
support for ICCVAM-related activities,
and conducts and publishes analyses
and evaluations of data from new,
revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative test methods
and strategies for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
Dated: January 6, 2021.
Brian R. Berridge,
Associate Director, National Toxicology
Program.
[FR Doc. 2021–00227 Filed 1–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase I: Improving Technologies to
Make Large-scale High Titer Phage Preps
(Topic 95).
Date: February 5, 2021.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E72A,
Rockville, MD 20892 (Virtual Meeting).
PO 00000
Frm 00066
Fmt 4703
Sfmt 9990
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3E72A, Rockville, MD
20892–9823, (240) 669–5023, fdesilva@
niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2018–1 Phase II: Improving Technologies to
Make Large-scale High Titer Phage Preps
(Topic 95).
Date: February 5, 2021.
Time: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E72A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3E72A, Rockville, MD
20892–9823, (240) 669–5023, fdesilva@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 5, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–00222 Filed 1–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Amended Notice
of Meeting
Notice is hereby given of a change in
the meeting of the Council of Councils,
January 29, 2021, 10:00 a.m. to 05:00
p.m., a virtual meeting, which was
published in the Federal Register on
November 25, 2020, 85 FR 75342.
The meeting notice is amended to
change the open session meeting end
time as follows: The open session will
now be held from 11:00 a.m. to 3:50
p.m.
Dated: January 5, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–00221 Filed 1–8–21; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\11JAN1.SGM
11JAN1
]]>Agencies
[Federal Register Volume 86, Number 6 (Monday, January 11, 2021)]
[Notices]
[Page 1982]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-00222]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase
I: Improving Technologies to Make Large-scale High Titer Phage Preps
(Topic 95).
Date: February 5, 2021.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3E72A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Frank S. De Silva, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3E72A,
Rockville, MD 20892-9823, (240) 669-5023, [email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2018-1 Phase
II: Improving Technologies to Make Large-scale High Titer Phage
Preps (Topic 95).
Date: February 5, 2021.
Time: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3E72A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Frank S. De Silva, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3E72A,
Rockville, MD 20892-9823, (240) 669-5023, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 5, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-00222 Filed 1-8-21; 8:45 am]
BILLING CODE 4140-01-P
